Free tool
FAERS Monitor: Aldactone
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 012151 or its brand name (Aldactone, Spironolactone). Reports on generic versions are filed under their own applications.
Reports
142,744
Serious
111,491
78% of reports
Hospitalization
67,450
Death reported
18,312
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea11,078
- fatigue8,762
- nausea8,345
- diarrhoea8,003
- acute kidney injury7,153
- dizziness6,673
- headache6,414
- hypotension6,175
- off label use6,086
- drug ineffective5,550
- fall5,362
- asthenia5,282
- death5,212
- vomiting5,144
- hyperkalaemia5,096
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,611 |
| 2005 | 1,925 |
| 2006 | 1,911 |
| 2007 | 1,861 |
| 2008 | 2,088 |
| 2009 | 2,528 |
| 2010 | 3,341 |
| 2011 | 3,581 |
| 2012 | 4,304 |
| 2013 | 3,937 |
| 2014 | 5,469 |
| 2015 | 7,144 |
| 2016 | 8,776 |
| 2017 | 8,042 |
| 2018 | 9,684 |
| 2019 | 9,988 |
| 2020 | 9,246 |
| 2021 | 8,774 |
| 2022 | 8,916 |
| 2023 | 9,822 |
| 2024 | 10,781 |
| 2025 | 10,709 |
| 2026 | 8,302 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,911,415 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hyperkalaemiaSignal | 5,096 | 24.9 | 24.2 | 100,002 |
| acute kidney injurySignal | 7,153 | 7.2 | 7.0 | 36,502 |
| hypotensionSignal | 6,175 | 4.6 | 4.5 | 17,298 |
| dyspnoeaSignal | 11,078 | 2.9 | 2.9 | 14,100 |
| fallSignal | 5,362 | 2.4 | 2.3 | 4,360 |
| astheniaSignal | 5,282 | 2.1 | 2.0 | 2,993 |
| dizziness | 6,673 | 2.0 | 1.9 | 3,293 |
| diarrhoea | 8,003 | 1.8 | 1.8 | 3,110 |
| fatigue | 8,762 | 1.7 | 1.6 | 2,393 |
| vomiting | 5,144 | 1.6 | 1.6 | 1,231 |
| nausea | 8,345 | 1.6 | 1.5 | 1,722 |
| headache | 6,414 | 1.5 | 1.5 | 1,136 |
| off label use | 6,086 | 1.0 | 1.0 | 4 |
| death | 5,212 | 0.9 | 0.9 | 72 |
| drug ineffective | 5,550 | 0.6 | 0.6 | 1,383 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.